Novo Nordisk govt vp of U.S. operations Dave Moore discusses the drugmaker’s newly launched once-daily oral weight-loss capsule on ‘The Claman Countdown.’
Wegovy’s oral model of its injectable weight-loss drug is seeing large curiosity, Novo Nordisk govt Dave Moore instructed FOX Enterprise on Friday.
Wegovy’s once-daily capsule, an oral spin-off of its injectable weight reduction remedy, was authorized in December 2025 by the Meals and Drug Administration as the primary oral GLP-1 drug and launched on U.S. markets Monday.
“There are such a lot of sufferers which were on the sidelines simply ready as a result of they did not actually see themselves treating with an injection,” Moore, Novo Nordisk’s govt vp of U.S. Operations, stated on “The Claman Countdown.” “Now that the capsule is accessible, we’re seeing a whole lot of pleasure and a whole lot of exercise.”
WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT
Wegovy injection pens organized in Waterbury, Vermont, on April 28, 2025. (Shelby Knowles/Bloomberg by way of Getty Pictures / Getty Pictures)
Drugmaker Novo Nordisk manufactures Wegovy. Moore instructed FOX Enterprise that medical trials present the capsule delivers comparable weight reduction outcomes to the injection.
“There is not that a lot of a distinction,” the drugmaker govt defined. “That is what we’re so enthusiastic about. That is what we’re so proud about at Novo Nordisk is that sufferers now haven’t got to choose. They do not should compromise.”
The capsule can be out there at 70,000 pharmacies nationwide, together with main retailers like CVS, Costco and Good Rx.
TARGET BEEFS UP PROTEIN, SUPPLEMENT OFFERINGS, CAPITALIZING ON WEIGHT LOSS DRUG TREND
Wegovy is pictured as an injectable prescription weight reduction drugs. (Michael Siluk/UCG/Common Pictures Group by way of Getty Pictures / Getty Pictures)
Pricing for the semaglutide capsule is decrease than that of the injectable model for these paying money. Eligible, insured clients pays about $25 a month whereas uninsured pays $149 a month, FOX Enterprise anchor Liz Claman reported.
Moore famous the capsule and injection price roughly the identical for Novo Nordisk to fabricate, however making the capsule reasonably priced was a precedence for the drugmaker.
Along with the lower cost, he additionally highlighted the secondary advantages related to Wegovy past weight reduction.
“Each the injection and the capsule have a secondary indication, and that’s to scale back the danger of heart problems,” Moore stated.
The FDA classifies the drug as a preventative coronary heart illness remedy.
AMERICA’S OBESITY CRISIS MEETS THE OZEMPIC BOOM AS DATA REVEALS GLP-1 HOT SPOTS
Whereas Wegovy’s capsule is the one oral GLP-1 remedy authorized by the FDA for weight reduction, Novo Nordisk’s rival Eli Lilly is reportedly nearing approval for its oral model.
Eli Lilly headquarters in Indianapolis, Indiana, on Could 3, 2023. (AJ Mast/Bloomberg by way of Getty Pictures / Getty Pictures)
Moore additionally addressed considerations about what occurs when sufferers cease taking GLP-1 drugs, noting that many expertise weight regain.
“When you go off therapy, seemingly the burden returns, and in order that extended therapy is essential,” he stated.
“Similar to in case you had been on a hypertension drugs or one for diabetes, long-term therapy is critical,” Moore added.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Claman requested whether or not Novo Nordisk is exploring options that might not require lifelong use.
“There may be a whole lot of R&D [research and development] that is happening, and naturally, we’re on the heart of that,” Moore stated.
